Commented Articles

PanNASH covers commented articles ans publications to acquire sufficient information, understanding, and skills to cope with NASH/NAFLD healthcare demands.

Noninvasive Tools for Diagnosing NASH: an expert panel consensus?

Authors: Jacobson IM, Wong VW, Castera L, et al.
Published in Journal of Clinical Gastroenterology 2022
Noninvasive tests (NITs) have been developed as an alternative to invasive liver biopsy, the current gold standard for non-alcoholic steatohepatitis (NASH) diagnosis and hepatic fibrosis stage identification. The use of NITs in clinical practice should facilitate the early diagnosis of high-risk non-alcoholic fatty liver disease (NAFLD).
Read MoreNoninvasive Tools for Diagnosing NASH: an expert panel consensus?

Advanced liver fibrosis and atrial fibrillation recurrence after ablation

Authors: Wang Z, Wang Y, Luo F, et al.
Published in Frontiers in Cardiovascular Medicine 2022
Clinical recommendations for patients with atrial fibrillation (AF) advise radiofrequency catheter ablation (RFCA) for symptom management and cardiovascular outcome improvement. However, approximately 50% of AF patients are affected by recurrent arrhythmia within 5 years of RFCA.
Read MoreAdvanced liver fibrosis and atrial fibrillation recurrence after ablation

Manganese exposure level: a biomarker of the development of NAFLD?

Authors: Liu J, Tan L, Liu Z, et al.
Published in Environmental Science and Pollution Research International 2022
Non-alcoholic fatty liver disease (NAFLD) has recently been regarded as a hepatic manifestation of metabolic syndrome (MetS) due to its similarities in aetiology with diabetes mellitus, obesity, and dyslipidaemia. Several studies in recent years have suggested that exposure toxic environmental compounds may contribute to liver disease onset.
Read MoreManganese exposure level: a biomarker of the development of NAFLD?

Lean NAFLD patients with hypertension: a higher risk of adverse outcomes

Authors: Lan Y, Lu Y, Li J, et al.
Published in Hepatology Communications 2022
Only a limited amount of data exists regarding the association between body mass index (BMI), non-alcoholic fatty liver disease (NAFLD), and adverse outcomes. It is known that obesity is a significant risk factor for NAFLD and its associated intra- and extrahepatic complications.
Read MoreLean NAFLD patients with hypertension: a higher risk of adverse outcomes

Depression in non-alcoholic fatty liver disease is associated with an increased risk of complications and mortality

Authors: Ng CH, Xiao J, Chew NWS, et al.
Published in Frontiers in Medicine 2022
It is known that NAFLD is associated with intra- and extra-hepatic complications, including increased risk of cardiovascular disease (CVD) and chronic kidney disease. Emerging evidence has also suggested the existence of an association between NAFLD and depression.
Read MoreDepression in non-alcoholic fatty liver disease is associated with an increased risk of complications and mortality

Metabolic syndrome: an upstream metabolic defect leading to manifestations in both the heart and liver?

Authors: Chen B, Tang WHW, Rodriguez M, et al.
Published in Seminars in liver disease 2022
Nonalcoholic fatty liver disease (NAFLD) is characterised by the presence of hepatic steatosis without significant alcohol consumption or concomitant liver disease. Cardiovascular disease (CVD) is a leading cause of death in people living with NAFLD.
Read MoreMetabolic syndrome: an upstream metabolic defect leading to manifestations in both the heart and liver?

Transient elastography measurements in paediatric patients

Authors: Brunnert L, Puasa ID, Garten A, et al.
Published in Frontiers in Endocrinology 2022
Transient elastography (TE) is a non-invasive, cost-efficient, and observer-independent approach to reliably detect fibrosis and steatosis. To estimate liver fibrosis, TE uses Liver Stiffness Measurement (LSM), while Controlled Attenuation Parameter (CAP) is used to assess the percentage of liver fat.
Read MoreTransient elastography measurements in paediatric patients

NAFLD–related HCC: Lower surveillance rates and cirrhosis prevalence

Authors: Tan DJH, Ng CH, Lin SY, et al.
Published in Lancet Oncology (March 2022)
Patients with non-alcoholic fatty liver disease (NAFLD) are at a higher risk of developing liver-related complications. This includes liver decompensation and hepatocellular carcinoma (HCC). Although this association is well-known, no comprehensive meta-analysis comparing the clinical presentation and outcomes of NAFLD-related HCC to that of non-NAFLD-related HCC currently exists.
Read MoreNAFLD–related HCC: Lower surveillance rates and cirrhosis prevalence

MAFLD-HCC in Italy: a rapidly increasing prevalence, a reduced cancer aggressiveness?

Authors: Vitale A, Svegliati-Baroni G, Ortolani A, et al.
Published in Gut (December 2021)
Non-alcoholic liver disease (NAFLD)’s current nomenclature supports an exclusionary diagnosis, i.e. based on the ruling out of other liver disease causes instead of active case-finding. As an alternative to NAFLD, an international panel of experts has recently proposed a new definition of NAFLD, termed metabolic dysfunction-associated fatty liver disease (MAFLD), based on active identification of its associated metabolic risk factors.
Read MoreMAFLD-HCC in Italy: a rapidly increasing prevalence, a reduced cancer aggressiveness?

Hepatocellular carcinoma surveillance in NAFLD patients

Authors: Cholankeril G, El-Serag H.
Published in Seminars in liver disease 2022
Nonalcoholic fatty liver disease (NAFLD) is characterised by the presence of hepatic steatosis without significant alcohol consumption or concomitant liver disease. Patients with NAFLD-related cirrhosis are at a high risk of developing liver complications, including hepatocellular carcinoma (HCC).
Read MoreHepatocellular carcinoma surveillance in NAFLD patients

NAFLD: current treatment and future treatment options

Authors: Paternostro R, Trauner M.
Published in Journal of Internal Medicine 2022
Nonalcoholic fatty liver disease (NAFLD) refers to the development of hepatic steatosis in the absence of secondary causes. Contrarily to nonalcoholic steatohepatitis (NASH), which refers to inflammation and ballooning with or without fibrosis, NAFLD involves all histopathological changes.
Read MoreNAFLD: current treatment and future treatment options

SUBSCRIBE & FOLLOW US

SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES